# Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments

> **NCT06905834** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Instituto de Investigación Biomédica de Salamanca** · enrollment: 30 (estimated)

## Conditions studied

- Dry Eye Disease (DED)
- Graft-Versus-Host Disease(GVHD)

## Interventions

- **DRUG:** Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC

## Key facts

- **NCT ID:** NCT06905834
- **Lead sponsor:** Instituto de Investigación Biomédica de Salamanca
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-06
- **Final completion:** 2028-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06905834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06905834, "Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06905834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*